Free Trial
NASDAQ:LRMR

Larimar Therapeutics Q1 2024 Earnings Report

Larimar Therapeutics logo
$3.91 +0.01 (+0.26%)
Closing price 08/28/2025 04:00 PM Eastern
Extended Trading
$3.97 +0.06 (+1.53%)
As of 08:34 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Larimar Therapeutics EPS Results

Actual EPS
-$0.27
Consensus EPS
-$0.24
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A

Larimar Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Larimar Therapeutics Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Thursday, May 9, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Larimar Therapeutics' Q3 2025 earnings is scheduled for Wednesday, October 29, 2025

Larimar Therapeutics Earnings Headlines

Q4 Earnings Forecast for LRMR Issued By Leerink Partnrs
This is my Christian duty
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.tc pixel
Wedbush Analysts Increase Earnings Estimates for LRMR
See More Larimar Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Larimar Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Larimar Therapeutics and other key companies, straight to your email.

About Larimar Therapeutics

Larimar Therapeutics (NASDAQ:LRMR), a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

View Larimar Therapeutics Profile

More Earnings Resources from MarketBeat